

Date: 26-June-2024

News Coverage of Press Release

“CCP Approves Acquisition of Two Japanese Pharmaceutical Products by Hilton Pharma”

CCP approves acquisition of two products of Eisai by Hilton Pharma

RECORDER REPORT

ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products of M/s Eisai Co Ltd, a Tokyo-based firm, by M/s Hilton Pharma Pvt Ltd.

The proposed transaction entails acquisition of two pharmaceutical products i.e. "Methycobal and Myonal" including their trademarks, know-how and records in terms of assets consequent to an Asset Purchase Agreement (APA). Whereas, APA was signed for the purpose of manufacturing and commercializing the products in Pakistan.

Hilton Pharma, since its incorporation in 1989, is involved in the business of manufacturing and distribution of medicinal products in Pakistan. The acquirer is also duly authorized by Drug Regulatory Authority of Pakistan to manufacture pharmaceutical products. Meanwhile, Eisai Co Ltd, a Japanese pharmaceutical company headquartered in Tokyo, is operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines.

The CCP's Phase-I competition assessment identified "Pharmaceutical – Myonal and Methycobal" as the relevant product market. The assessment revealed that pursuant to a License Agreement Hilton Pharma is already manufacturing and selling the aforementioned products but that agreement will be terminated after the completion of this transaction. Moreover, Hilton Pharma has a nominal market share which will remain unchanged after the transaction. Ultimately, the proposed acquisition will not result in Hilton Pharma gaining dominance in the relevant market.

This move is expected to bring enhanced expertise to boost local drug production in Pakistan. By clearing this acquisition, the CCP aims to cultivate self-reliance thus ensuring advanced but domestic choices in pharma sector within the country.

Hilton's acquisition of Eisai products approved

By Our Staff Reporter

ISLAMABAD: The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products from Tokyo-based Eisai Co. Ltd. by Hilton Pharma (Pvt) Ltd. The acquisition includes the rights to manufacture and commercialise the drugs Methycobal and Myonal in Pakistan.

The transaction involves the transfer of trademarks, know-how and records related to these products under an asset purchase agreement signed between the two companies. This agreement aims to facilitate the production and distribution of these medications within Pakistan.

Hilton Pharma, established in 1989, has been manufacturing and distributing medicinal products in the country. The company is authorised by the Drug Regulatory Authority of Pakistan to produce pharmaceutical items.

Eisai Co. Ltd., headquartered in Tokyo, is a global leader in pharmaceutical research, development, manufacturing, and marketing, with a strong focus on prescription medicines.

CCP approves acquisition of two Japanese pharma products by Hilton Pharma

PROFIT

NEWS DESK

The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products of M/s Eisai Co. Ltd, a Tokyo-based firm, by M/s Hilton Pharma Pvt Ltd. The proposed transaction entails the acquisition of two pharmaceutical products, i.e., 'Methycobal and Myonal,' including their trademarks, know-how, and records in terms of assets consequent to an Asset Purchase Agreement (APA). The APA was signed for the purpose of manufacturing and commercializing the products in Pakistan. Hilton Pharma, since its incorporation in 1989, is involved in the business of manufacturing and distribution of medicinal products in Pakistan. The acquirer is also duly authorised by the Drug Regulatory Authority of Pakistan to manufacture pharmaceutical products. Meanwhile, Eisai Co. Ltd, a Japanese pharmaceutical company headquartered in Tokyo, is operating globally in terms of R&D, manufacturing, and marketing, with a strong focus on prescription medicines. The CCP's Phase-I competition assessment identified 'Pharmaceutical – Myonal and Methycobal' as the relevant product market. The assessment revealed that pursuant to a License Agreement, Hilton Pharma is already manufacturing and selling the aforementioned products but that agreement will be terminated after the completion of this transaction. Moreover, Hilton Pharma has a nominal market share which will remain unchanged after the transaction. Ultimately, the proposed acquisition will not result in Hilton Pharma gaining dominance in the relevant market. This move is expected to bring enhanced expertise to boost local drug production in Pakistan.

ہلٹن فارما کو 2 ادویہ سازی مصنوعات تیار کرنے کی اجازت

میٹھیکو بل اور میونل کی منظوری کا مقصد خود انحصاری کا فروغ ہے، CCP حکام

اسلام آباد (اوصاف نیوز) کمپنیشن کمیشن آف پاکستان (سی سی پی) نے ہلٹن فارما کو ٹوکیو میں قائم فرم اے زائی کولمیڈ کی دو فارماسیوٹیکل پراڈکٹ کے حصول کی منظوری دے دی ہے۔ مجوزہ ٹرانزیکشن میں دو دواسازی کی مصنوعات میٹھیکو بل اور میونل، (باقی صفحہ 6 بقیہ نمبر 30)

30

ہلٹن فارما اجازت

اوصاف

کا حصول شامل ہے۔ اس حصول میں ان پراڈکٹ کے ٹریڈ مارکس، معلومات، ریکارڈ اور اثاثہ جات بھی شامل ہیں۔ یہ ٹرانزیکشن خریداری کے معاہدے (اے پی اے) کے نتیجے میں عمل میں لائی گئی ہے۔ اے پی اے معاہدے پر پاکستان میں مصنوعات کی تیاری اور کمرشلائزیشن کے حوالے سے دستخط کیے گئے تھے۔ ہلٹن فارما، 1989 میں اپنے قیام کے بعد سے، پاکستان میں فارماسیوٹیکل پراڈکٹ کی تیاری اور تقسیم کے کاروبار سے منسلک ہے۔ ہلٹن کو ڈرگ ریگولیٹری اتھارٹی آف پاکستان کی طرف سے دواسازی کی مصنوعات تیار کرنے کی باقاعدہ اجازت دی گئی ہے۔

CCP Approves Acquisition Of Two Japanese Pharmaceutical Products By Hilton Pharma

June 25, 2024 | Health



The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products of M/s Eisai Co. Ltd, a Tokyo-based firm, by M/s Hilton Pharma Pvt Ltd.

The proposed transaction entails acquisition of two pharmaceutical products i.e. 'Methycobal and Myonal' including their trademarks, know-how and records in terms of assets consequent to an Asset Purchase Agreement (APA). Whereas, APA was signed for the purpose of manufacturing and commercializing the products in Pakistan. CCP Approves Acquisition of Luxembourg Firm with presence in Pakistan's solar market

Hilton Pharma, since its incorporation in 1989, is involved in the business of manufacturing and distribution of medicinal products in Pakistan. The acquirer is also duly authorized by Drug Regulatory Authority of Pakistan to manufacture pharmaceutical products. Meanwhile, Eisai Co Ltd, a Japanese pharmaceutical company headquartered in Tokyo, is operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines.

The CCP's Phase-I competition assessment identified 'Pharmaceutical – Myonal and Methycobal' as the relevant product market. The assessment revealed that pursuant to a License Agreement Hilton Pharma is already manufacturing and selling the aforementioned products but that agreement will be terminated after the completion of this transaction. Moreover, Hilton Pharma has a nominal market share which will remain unchanged after the transaction. Ultimately, the proposed acquisition will not result in Hilton Pharma gaining dominance in the relevant market.

This move is expected to bring enhanced expertise to boost local drug production in Pakistan. By clearing this acquisition, CCP aims to cultivate self-reliance thus ensuring advanced but domestic choices in pharma sector within the country.

<https://newztodays.com/ccp-approves-acquisition-of-two-japanese/>

26-June-2024

Online

CCP approves Hilton Pharma's purchase of 2 Japanese pharmaceutical products



June 27, 2024 (MLN): The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products of Eisai Co. Ltd, a Tokyo-based firm, by Hilton Pharma Pvt Ltd.

The proposed transaction entails the acquisition of two pharmaceutical products i.e. 'Methycobal and Myonal' including their trademarks, know-how and records in terms of assets consequent to an Asset Purchase Agreement (APA).

Whereas, APA was signed for the purpose of manufacturing and commercializing the products in Pakistan.

Hilton Pharma, since its incorporation in 1989, is involved in the business of manufacturing and distribution of medicinal products in Pakistan.

The acquirer is also duly authorized by Drug Regulatory Authority of Pakistan to manufacture pharmaceutical products.

Meanwhile, Eisai Co Ltd, a Japanese pharmaceutical company headquartered in Tokyo, is operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines.

The CCP's Phase-I competition assessment identified 'Pharmaceutical – Myonal and Methycobal' as the relevant product market.

The assessment revealed that pursuant to a License Agreement Hilton Pharma is already manufacturing and selling the aforementioned products but that agreement will be terminated after the completion of this transaction.

Moreover, Hilton Pharma has a nominal market share which will remain unchanged after the transaction. Ultimately, the proposed acquisition will not result in Hilton Pharma gaining dominance in the relevant market.

This move is expected to bring enhanced expertise to boost local drug production in Pakistan.

By clearing this acquisition, CCP aims to cultivate self-reliance thus ensuring advanced but domestic choices in pharma sector within the country.

<https://mettisglobal.news/ccp-approves-hilton-pharmas-purchase-of-2-japanese-pharmaceutical-products/>

CCP approves acquisition of two Japanese pharma products by Hilton Pharma



Posted on June 26, 2024
by darion

The Competition Commission of Pakistan (CCP) has approved the acquisition of two pharmaceutical products of M/s Eisai Co. Ltd. a Tokyo-based company by M/s Hilton Pharma Pvt Ltd.

The proposed transaction entails the acquisition of two pharmaceutical products, i.e., 'Methycobal and Myonal,' including their trademarks, know-how, and records in terms of assets consequent to an Asset Purchase Agreement (APA). The APA was signed for the purpose of manufacturing and commercializing the products in Pakistan.

Hilton Pharma, since its incorporation in 1989, is involved in the business of manufacturing and distribution of medicinal products in Pakistan.

The acquirer is also duly authorized by the Drug Regulatory Authority of Pakistan to manufacture pharmaceutical products.

Meanwhile, Eisai Co. Ltd, a Japanese pharmaceutical company headquartered in Tokyo, is operating globally in terms of R&D, manufacturing, and marketing, with a strong focus on prescription medicines.

The CCP's Phase-I competition assessment identified 'Pharmaceutical – Myonal and Methycobal' as the relevant product market. The assessment revealed that pursuant to a License Agreement, Hilton Pharma is already manufacturing and selling the aforementioned products but that agreement will be terminated after the completion of this transaction.

Moreover, Hilton Pharma has a nominal market share which will remain unchanged after the transaction. Ultimately, the proposed acquisition will not result in Hilton Pharma gaining dominance in the relevant market.

This move is expected to bring enhanced expertise to boost local drug production in Pakistan. By clearing this acquisition, CCP aims to cultivate self-reliance, thus ensuring advanced but domestic choices in the pharma sector within the country.

<https://solondais.fr/2024/06/26/news160265/ccp-approves-acquisition-of-two-japanese-pharma-products-by-hilton-pharma/>